Invectys, Inc. Announces Presentation of First-in-Human Clinical Trial Design on HLA-G–Targeted CAR T Therapy at ASCO 2025 Houston, TX – May 28, 2025…
FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma Houston, TX, USA, July 31, 2023 – Invectys,…
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership Houston, TX, USA, July 13, 2023 – Invectys, Inc., a clinical-stage…
Invectys awarded “2023 Best Translational Development” by the MATWIN international Board Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…
Invectys is part of project “Melomanes”! Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma,…
INVECTYS, INC. TO PARTICIPATE IN THE 41ST JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023 Houston, Texas, January 5, 2023 – Invectys, Inc. “Invectys”,…
Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy FDA granted IND clearance for IVS-3001, Invectys’s lead…
FRANÇOIS LESCURE, GENERAL MANAGER OF INVECTYS SAS, TO PARTICIPATE IN THE ABBVIE PARTNERING DAY IN PARIS, FRANCE ON OCTOBER 4TH, 2022 Paris, France, September…
